Funding

California-Based Moonwalk Biosciences Raises $70M in Series B Financing

Sep 9, 2026 | By Devin Jacobs

SUMMARY

Moonwalk Biosciences raised $70M in Series B funding.
The funding will support drug development.
Moonwalk develops RNA medicines.

Moonwalk Biosciences, a South San Francisco, CA-based provider of adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, has raised $70 million in a Series B funding round co-led by Alpha Wave and YK Bioventures.

The round also saw participation from Eli Lilly and Company, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures, and Future Ventures.

The company will use the funding to advance its lead candidate MW101, expand its tissue-targeted siRNA pipeline, and further develop its discovery platform.

Funding Snapshot

Metric	Details
Fundraise Amount	$70 million
Funding Round	Series B
Lead Investors	Alpha Wave & YK Bioventures
Company	Moonwalk Biosciences
Sector	Biotechnology & RNAi Therapeutics
Headquarters	South San Francisco, California, USA

RECOMMENDED FOR YOU

Funding

Aboard Closes Pre-Series A Funding Led by Ondine Capital

Devin Jacobs

May 23, 2026

Funding

ApartmentIQ Raises $25 Million to Accelerate AI-Powered Real Estate Solutions

Startuprise

Aug 12, 2026

Funding

Fields Good Raises $1.8M in Pre-Seed Funding

Devin Jacobs

May 28, 2026

About Moonwalk Biosciences

Founded in 2022 by Alex Aravanis, Arash Jamshidi, Justin Valley, Moonwalk Biosciences develops adipose-targeted RNAi medicines for obesity and cardiometabolic diseases. Its AI enabled discovery platform combines human genetics, epigenomics, and multi omics with proprietary adipose selective siRNA chemistry to identify and validate novel therapeutic targets.

Core offerings include:

Adipose-targeted RNAi medicines
Tissue-targeted siRNA programs
AI-enabled drug discovery
Obesity and cardiometabolic disease therapies

Core Technologies / Products / Services

Capability/Product	Application/Use Case
MW101	Lead obesity development candidate
Adipose-targeted siRNA	Selective delivery to adipose tissue
AI-enabled discovery platform	Identifying novel therapeutic targets
Multi-omics discovery	Understanding adipose biology and metabolic pathways

Leadership Comments

“Obesity places an extraordinary physical and emotional burden on millions of people,” said Alex Aravanis, M.D., Ph.D., CEO & Co-Founder, Moonwalk Biosciences. “This financing brings us closer to developing a new generation of adipose-targeted medicines designed to improve outcomes for people living with obesity and related cardiometabolic diseases.”

“Obesity is one of the most significant global health challenges, and Moonwalk is pursuing a fundamentally different approach to treating it,” said Rick Gerson, co-founder, Chairman and CEO of Alpha Wave Global. “By targeting adipose tissue directly, Moonwalk may redefine how obesity is treated by delivering therapies with the potential for durable efficacy, lean muscle preservation and infrequent dosing.”